| ABSTRACT Objective: To evaluate the efficacy and safety of dapaglifozin（DAPA） combined with insulin（INS） in patients with type 2 diabetes mellitus. Methods:PubMed, The Cochrane Library, Embase, WanFang Data, SinoMed and CNKI were electronically searched to collect the randomized controlled trials (RCTs) on DAPA combined with INS in patients with type 2 diabetes mellitus from inception to June 2018. References of included studies were also retrieved. Two reviewers independently screened RCTs, extracted data and assessed the risk of bias of RCTs. Then, Meta analysis was performed by using RevMan 5.3 software. Results:Five RCTs including 948 patients were included. The results of meta analysis showed that compared to INS group, DAPA combined with INS groups significantly reduced HbA1c levels (%) (MD=-0.50, 95%CI -0.88 to -0.12, P<0.05), body weight (kg) (MD=-2.00, 95%CI -2.89 to -1.11, P<0.05) and total daily insulin dose (IU) (MD=-5.14, 95%CI -9.21 to -1.07, P<0.05). There was no statistically signicant diference between two groups on FPG levels and the incidence of adverse events（AEs）, hypoglycemic,urinary tract infections and genital infections (P＞0.05). Conclusion:Based on this rexiew, DAPA combined with INS can improve glycemic control, reduce body weight and total daily insulin dose without increase of total AEs, hypoglycemic, urinary tract infections and genital infections in patients with type 2 diabetes mellitus. Due to limited quality and quantity of the included studies, more high quality studies are needed to verify above conclusion. |
